Status:
RECRUITING
Safety and Effectiveness of No-touch Technique for Ascending Aorta in MICS-CABG
Lead Sponsor:
Peking University Third Hospital
Conditions:
Coronary Artery Bypass Grafting
Off-pump Coronary Artery Bypass
Eligibility:
All Genders
Brief Summary
The goal of this single-center prospective cohort study is to compare perioperative safety metrics and follow-up survival analyses in patients receiving Minimally Invasive Cardiac Surgery Coronary Art...
Detailed Description
STATUS OF THE STUDY: Coronary Artery Bypass Grafting (CABG) surgery and Percutaneous Coronary Intervention (PCI) are important methods to address myocardial ischemia in coronary artery disease. CABG s...
Eligibility Criteria
Inclusion
- Patients with angina pectoris who experience functional limitations in daily life and work despite conservative medical treatment and who require coronary artery bypass grafting surgery, as confirmed by coronary angiography, are eligible for enrollment.
- Patients with calcification of the ascending aorta, as confirmed by CT, who are not suitable for sidewall clamping are also eligible for enrollment.
Exclusion
- The patient presents with an old, large myocardial infarction with no surviving myocardium, as evidenced by both isotope and echocardiographic imaging. This is a group of patients who are prone to complications, including significant cardiac enlargement, a cardiothoracic ratio greater than 0.75, an ejection fraction (EF) less than 30%, a left ventricular diameter (LVDd) greater than 70mm, the presence of a left ventricular ventricular wall tumor, or severe arrhythmia. Intraoperative hemodynamic instability;
- Valve surgery or other intracardiac surgery at the same time;
- Patients expected to undergo extracorporeal circulation surgery;
- Poor myocardial infarction conditions, extensive lesions, distal or full diffuse stenosis, or lumen diameter less than or severe calcification that cannot be anastomosed.
- Previous open heart surgery.
- Patients with preoperative hemodynamic instability requiring emergency surgery.
- Other conditions include terminal malignant tumors, uncontrollable infections, bleeding, persistent progressive degenerative systemic diseases, severe brain injuries, and multiple organ failure. Additionally, other significant organ function serious impairments, such as severe liver function impairment, severe heart failure, or cardiogenic shock, may also be considered contraindications. Inability to tolerate surgery may also be considered a contraindication.
- The participant declines to take part in this study.
Key Trial Info
Start Date :
June 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT07172620
Start Date
June 1 2025
End Date
December 31 2030
Last Update
September 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100191